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in cost between two or more treatment alter-
natives is weighted against the difference in 
effects in order to calculate the results expres-
sed as a ratio: the incremental cost-effective-
ness ratio (ICER). The recommended effect 
measure used by agencies such as the NICE 
when performing a CEA is quality-adjusted 
life years (QALYs) [1]. The QALY combines 
life years with the health state utility, often 
expressed in terms of health-related quality 
of life (HRQoL).
Health state utility (or HRQoL) for QALY 
calculations can be obtained in different 
ways. Health economics is often associa-
ted with the theories of welfare economics. 
Within the field of welfare economics, it is 
INTRODUCTION
Decisions on resource allocation and pri-
ority setting are a reality in the health care 
sector. Decision makers need to battle the 
gap between available resources and the in-
creasing demand for health care. In this con-
text, health economic analyses studying costs 
and effects of technologies are important in 
enabling informed decisions about resource 
allocation. Several agencies, including the 
National Institute for Health and Clinical 
Excellence (NICE) in England and Wales, 
require economic evidence to be presented 
in the form of cost-effectiveness analyses 
(CEAs) [1]. In these analyses, the difference 
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ABSTRACT
OBJECTIVE: The aim of this paper is to demonstrate how the choice of patient versus proxy ratings of patient health-
related quality of life (HRQoL) in dementia, for use in cost-effectiveness analyses (CEAs), could potentially affect resource 
allocation in health care.
METHODS:A model of Alzheimer’s disease (AD) based on cognitive ability was used to assess the consequences of using 
HRQoL ratings from either patients themselves or proxies if a new treatment was to be introduced. The model was based 
on previously published data on costs related to AD stages as well as HRQoL ratings from AD patients and from their 
caregivers as proxy raters.
RESULTS:The results show that there can be large differences in the results of the CEAs depending on whether the ratings 
of patients’ HRQoL were made by the patients themselves or by the proxy. When patient self-ratings of HRQoL were used, 
the cost/quality-adjusted life year (QALY) gained was much higher as compared to the scenario when proxy ratings were 
used for the same analysis.
CONCLUSIONS: The choice of patient self-ratings compared to proxy ratings of patients’ HRQoL can have a substantial 
effect on the results of CEAs. These differences in results may have an important impact on decision making and, ultima-
tely, on resource allocation. In order to critically appraise the results of CEA studies in dementia we advise that both patient 
and proxy ratings are used in the CEA. To decide on methodology it is of great importance that focus is directed towards 
determining the most valid way to measure HRQoL in AD.
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tations and poor patient insight in dementia 
[7], both the proxy ratings and the patients’ 
own ratings have been questioned regarding 
validity. It has been argued that since it is not 
established who is the most appropriate rater 
in dementia – the patient or the proxy – data 
should be gathered from both [10].
Depending on who the rater of a patient’s 
HRQoL is, the patient or a proxy, the result 
of the CEA, i.e., the ICER, is likely to differ. 
The discrepancies between patient and proxy 
ratings in dementia are well known, but to 
what extent this has an impact on the results 
of CEAs has, to our knowledge, not been 
previously studied. This information is, ho-
wever, of great importance when it comes to 
deciding on method and critically appraising 
results of CEA studies. If the differences are 
sufficiently large, the choice of rater could 
ultimately lead to different decisions concer-
ning resource allocation in health care.
AIM
The aim of this paper is to demonstrate how 
the choice of rater, patient self-rater or care-
giver proxy rater of the patient’s HRQoL in 
dementia, for use in CEAs, could potentially 
affect resource allocation within health care.
METHODS
Using a health economic model, we investi-
gated the impact of different raters (patient 
and proxy) of patient HRQoL on the ICER. 
The model simulates the natural history of 
Alzheimer’s disease (AD) and calculates the 
cost-effectiveness of a new hypothetical tre-
atment slowing the progression of AD.
THE HEALTH ECONOMIC MODEL
A Markov model was constructed to model 
the progression of AD in four health states, 
from the onset of cognitive impairment to se-
vere cognitive impairment (Figure 1). 10,000 
individuals enter the model in the onset of 
cognitive impairment health state and can 
thereafter progress to a more severe cognitive 
health state with a monthly probability 
(monthly cycle length). Onset of cognitive 
impairment, progression, and health states 
were modeled based on Mini-Mental State 
Examination (MMSE) scores. The MMSE 
[11] is a common instrument for measuring 
cognitive ability in dementia. It includes que-
stions on orientation, registration, attention 
and calculation, memory, language, spatial 
ability, and ability to follow instructions. The 
score ranges from 0 to 30, where 30 repre-
sents high cognitive ability. In the model, on-
set of cognitive impairment was defined as a 
assumed that the judge of a person’s utility 
should always be the affected individual. 
Summarizing the tenet of “Individual sove-
reignty” within the framework of welfare 
economics, Hurley (2000, p. 60) [2] writes: 
«Individual sovereignty asserts that indivi-
duals are the best judges of their own welfa-
re; that any assessment of individual welfare 
should be based on a person’s own judgment. 
It rejects paternalism, the notion that a third 
party may know better than the individuals 
themselves what is best for them».
Whose preferences for valuing HRQoL 
(HRQoL will be the term used hereafter in 
the present study) should be used is, howe-
ver, a much debated subject. Many argue that 
the preferences of the public should be used 
rather than those of the individual, and one 
argument for this is that when a societal per-
spective (i.e., the argument that all relevant 
costs and effects that arise within society 
should be included) is advocated for the he-
alth economic analyses, then the preferences 
for different health states should be gathered 
from the general public [3]. Dolan (1999) ar-
gues that the issue boils down to whether or 
not the fact that persons in poor health states 
may adapt to, or cope with, their situation, 
and consequently not assign the health state 
the “true” value, should be taken into account 
[4].
Another dimension related to the issue of 
whose preferences to use arises when a per-
son, due to, e.g., young age (small children) 
or cognitive impairment/dementia, has diffi-
culties stating their own preferences or rating 
their own health state. In these situations, 
proxy raters are often used as a representa-
tive of the patient. A proxy is a person who 
is close to, and has knowledge about, the pa-
tient.
Within the field of dementia, where the issue 
of patient self-ratings versus proxy ratings is 
a well-acknowledged methodological chal-
lenge, research has shown that there are dif-
ferences between self-ratings of the persons 
with dementia and proxy ratings. Proxy ra-
tings of the patients’ HRQoL in dementia are 
lower than the patients’ own ratings of their 
HRQoL [5-9]. Sands et al. (2004) [5] set out 
to explain the differences in subjective quali-
ty of life (QoL) ratings between patients with 
mild to moderate dementia and their caregi-
ver proxies, and conclude that the difference 
could be related to factors such as level of 
caregiver burden, with a higher burden level 
meaning lower rating of the patients’ QoL as 
compared to the patients’ own rating. As the-
re may be issues of bias concerning caregiver 
proxy ratings [5] and questions concerning 
patients’ own ratings due to cognitive limi-
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[17]. The EQ-5D instrument includes five di-
mensions: mobility, self-care, usual activi-
ties, pain/discomfort, and anxiety/depression, 
and has three response options that corre-
spond to: “no problems”, “moderate pro-
blems”, and “severe problems”. The EQ-5D 
has a possible score ranging from -0.594 to 1, 
where 1 represents full health [18]. The pa-
tients in the Jönsson et al. [7]  study answered 
the EQ-5D themselves or with help from an 
interviewer. The HRQoL values were di-
scounted using a 3% rate.
RESULTS
The health economic model in the present 
study was used to illustrate the result of a 
AD stages MMSE score
EQ-5D HRQoL
Patient ratings Proxy ratings
Stage 1 21-25 0.85 0.65
Stage 2 15-20 0.83 0.52
Stage 3 10-14 0.73 0.51
Stage 4 0-9 0.78 0.40
Table II. Model data – Mini-Mental State Examination (MMSE) scores and health-
related quality of life (HRQoL) scores. Data retrieved from Jönsson et al [7]
AD = Alzheimer’s disease
MMSE score of ≤ 24 [12]. The progression in 
the model was based on a study by Mendion-
do et al. [13]. In this study, Mendiondo et al. 
presented mean MMSE change per year for 
different MMSE values. These progression 
rates were incorporated in the model to mo-
del the MMSE progression, and thus transi-
tions between the health states in the model. 
In each cycle, all individuals are at risk of 
death through all cause mortality [14]. The 
starting age of the patients in the model was 
75. The simulations were run until all pa-
tients had moved through the model, from 
stage 1 to death.  
Based on this model of the natural progres-
sion of AD, we created a strategy whereby 
a hypothetical treatment of AD was introdu-
ced. In the base case scenario, the treatment 
would decrease the monthly deterioration of 
MMSE by 10%, but add an additional cost 
of € 100 per month. In addition, we ran the 
model for scenarios of treatment effects of 
5%, 6%, 7%, 8%, and 9% in order to illustra-
te how the result would differ depending on 
choice of rater and also depending on diffe-
rent treatment effects.
COSTS
Costs associated with the different stages of 
AD were retrieved from a study by Jönsson et 
al. [15] that included 272 patients and their 
caregivers. In that article, the authors had cal-
culated mean annual costs for each of the 
MMSE stages [15] (Table I). The mean costs 
included costs for medical care (pharmaceu-
ticals), in- and outpatient care, community 
care (special housing, home help, day center 
visits, etc.), and informal care performed by 
family caregivers [15]. The costs were di-
scounted using a 3% rate.
HEALTH-RELATED 
QUALITY OF LIFE
Data on HRQoL for the analysis were retrie-
ved from a study by Jönsson et al. [7] which 
measured patient and proxy HRQoL weights 
for the different stages of dementia (Table II). 
The total population in the Jönsson et al. [7] 
study was 272 patients and their caregivers 
(proxies) who were mostly spouses or 
children. The proxies were asked to rate how 
they judged the patients’ HRQoL [16]. The 
patients were diagnosed with possible or pro-
bable AD and the mean age was 75.9 years 
[7]. The ratings retrieved from the Jönsson et 
al. study [7] used in the present article are the 
ones where both patient and caregiver ratings 
were available. The HRQoL in the article [7] 
was collected using the EQ-5D instrument 
Stage 4 MMSE
0-9
Stage 2 MMSE
15-20
Stage 3 MMSE
10-14
Stage 1 MMSE
21-24
Death
Figure 1. Markov model describing the four different stages of dementia
MMSE = Mini-Mental State Examination
AD stages MMSE score Mean annual cost/patient (€)*
Stage 1 21-25 8,699
Stage 2 15-20 17,044
Stage 3 10-14 21,007
Stage 4 0-9 34,718
Table I. Model data – Mini-Mental State Examination (MMSE) scores and costs. 
Data retrieved from Jönsson et al [15]
* Values for 2003
AD = Alzheimer’s disease
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proxy HRQoL ratings are above the WTP le-
vel of € 50,000. At higher treatment effects, 
the ICERs based on proxy ratings are under 
the WTP levels of € 50,000, around € 30,000 
at a treatment effect of 9% and also under € 
20,000 at the highest treatment effect used in 
the present study, of 10%. The ICERs from 
the analyses based on patient self-ratings are, 
however, never below the WTP level of € 
50,000.
The National Institute for Health and Clinical 
Excellence (NICE) has defined a value range 
of £ 20,000-30,000 (approximately € 22,100-
33,200) for cost per QALY gained to illustra-
te whether a technology is considered an ef-
fective use of resources [1]. Based on this 
value range, the choice of rater, patient or 
proxy, may have an important impact on re-
source allocation.
DISCUSSION
In the present paper, we have illustrated that 
the choice of rater of a patient’s HRQoL in 
dementia has an important impact on the re-
sults of the CEA, and may also have an effect 
on decision making. Depending on the choi-
ce of rater, the value of the ICER will change 
dramatically. As shown in our analysis, the 
ICER would differ between € 53,600 for 
the new, hypothetical, treatment if patient 
ratings were used and € 15,200 if proxy ra-
tings were used. Applying the value range of 
£ 20,000-30,000 (approximately € 22,100-
33,200) for cost per QALY gained, set by the 
NICE [1], it is clear that the choice of rater 
could have a substantial impact on the deci-
sion on whether or not to fund the new tre-
atment. For a technology with an ICER > € 
33,200 per QALY gained, strong arguments 
concerning, e.g., considerable benefits not 
captured by the QALY are needed in order 
for the technology to be included in public 
funding [1]. From the example in the present 
study, this would mean that if proxy ratings 
were used for the analysis, the treatment un-
der investigation would be considered cost-
effective; by contrast, if the HRQoL ratings 
of the patients themselves were used, gene-
rating a substantially higher cost/QALY gai-
ned, the treatment would not be regarded as 
cost-effective.
Rating HRQoL when diagnosed with demen-
tia is linked to a number of challenges, such 
as lack of insight [6] and difficulties in com-
prehending the questions, due to cognitive 
impairment. The validity and reliability of 
patient self-ratings in dementia has been que-
stioned [6,19]. Patients with AD, regardless 
of stage of the disease, rate their HRQoL as 
relatively high [7]. For example, the lowest 
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Figure 2. Incremental cost-effectiveness ratios (ICERs) for different levels of 
treatment effect, based on patient self-ratings and proxy ratings of patient health-
related quality of life (HRQoL). Three different levels of willingness to pay (WTP) 
for 1 quality-adjusted life year (QALY) gained are shown
CEA when both patient and proxy ratings of 
the patient’s HRQoL are used for the same 
analysis. The results show that there may be 
large differences in the results of a CEA, de-
pending on whether patient-rated or proxy-ra-
ted HRQoL is used (Table III). When patient 
self-rated HRQoL was used for the analysis 
in the present study, the cost per QALY gai-
ned (the ICER) was approximately € 53,600. 
When proxy-rated patient HRQoL was used 
for the same analysis, the cost per QALY gai-
ned was considerably lower, approximately € 
15,200 (Table III).
The results of the scenarios using different 
treatment effects are shown in Figure 2, toge-
ther with different levels of willingness to 
pay (WTP) for 1 QALY gained, of € 20,000, 
€ 30,000, and € 50,000, respectively. The re-
sults show that at lower treatment effects (5-
7%), the ICERs based on both patient and 
Patient self-rated 
HRQoL
Proxy-rated 
HRQoL
Cost, untreated (€) 210,003 210,003
Cost, treated (€) 211,211 211,211
Incremental cost (€) 
(Cost, untreated – Cost, treated)
1,208 1,208
QALYs, untreated 7.087 4.360
QALYs, treated 7.109 4.439
Incremental QALYs 
(QALYs, untreated – QALYs, treated)
0.023 0.079
ICER € 53,619 € 15,213
Table III. Mean differences per patient in the results between patient-rated 
health-related quality of life (HRQoL) and proxy-rated HRQoL
ICER = incremental cost-effectiveness ratio; QALYs = quality-adjusted life years
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It has further been debated who the most 
valid proxy is, as different proxies (family 
caregiver proxies or physician proxies) may 
yield different results when it comes to rating 
dementia patients’ HRQoL [6]. Who the ap-
propriate proxy rater is has yet to be establi-
shed [6].
Due to the large differences in the ICERs, 
depending on whose ratings are used, a mi-
nimum requirement when performing a CEA 
in AD should therefore be to use ratings from 
both patients and proxies. As the scenarios 
with different treatment effect showed (see 
Figure 2), the choice of rater does not always 
affect the interpretation of the results of the 
CEA. This should therefore be displayed. 
Displaying the results of both patient and 
proxy ratings will make it possible to make 
comparisons and to critically appraise the re-
sults of the analysis. Including the ratings of 
both patients and proxies has been previously 
recommended when it comes to measuring 
QoL in dementia [10]. This methodological 
issue and these findings may also be found in 
other areas where proxy ratings are common 
and where there are differences between dif-
ferent raters.
METHODOLOGICAL 
CONSIDERATIONS
This article employs a modeling approach 
to illustrate the methodological question 
under investigation. The model used in 
the present article does not claim to reflect 
“medical actuality”, but uses a fictitious 
scenario based on a hypothetical treatment. 
Several assumptions were made when de-
signing the model, an important one being 
that AD stages are determined by cogniti-
ve ability (based on MMSE scores) only. 
Dementia is a complex disease including 
different symptoms, of which cognitive 
ability is one. To measure and model stages 
of AD based only on cognitive ability has 
its limitations [21] and has been criticized 
[22]. The progression of AD includes dete-
rioration of cognitive and functional ability, 
behavioral aspects, and mood [22]. The aim 
of the present study was to examine diffe-
rences between patient and proxy ratings of 
HRQoL and their potential consequences 
for decision making. The model only simu-
lates deterioration of cognitive ability and 
consequences for decision making depen-
ding on rater. We suggest that further stu-
dies more comprehensively should reflect 
the complexity of dementia progression, 
also using longer term cost and utility data 
from clinical studies in the model in order to 
fully investigate these matters.
ratings from the persons with AD used in 
the present model, data from Jönsson et al. 
[7], were from patients at AD stage 3, with 
a EQ-5D HRQoL weight of 0.73, while the 
highest were from AD patients at stage 1, 
with a HRQoL rating of 0.85 (shown in Table 
II). This could be compared to EQ-5D ratings 
from the Swedish general population, which 
on average are 0.79 in the age group 70-79 
years [20]. Departing from the example in the 
present study, the use of self-ratings of the 
patients would mean that the treatment would 
not be considered cost-effective. Because of 
the difficulties of self-ratings in AD due to 
the nature of the disease, it can be argued that 
using patient self-ratings, with its potential 
consequences for resource allocation, would 
not be ethically just.
Proxy ratings of the patient’s HRQoL are 
often used as an alternative to patient self-
ratings when the patient is suffering from 
cognitive impairment (see e.g. [19]). Proxy 
ratings of patient HRQoL in AD using the 
EQ-5D have been shown to strongly relate to 
cognitive functioning [7]. Proxy ratings are, 
however, not without challenges. There is a 
low level of agreement between proxy ra-
tings and patient self-ratings, and factors re-
lated to the proxy (level of caregiver burden), 
and not necessarily to the patient, have been 
shown to influence proxy ratings [5]. It could 
be argued that using the ratings of a proxy 
would be unethical as it is difficult to assess 
what the “real” HRQoL of the patient is. The 
validity of self-ratings of HRQoL by the pa-
tients themselves in the more severe stages 
of dementia is, however, probably conside-
red as questionable due to the nature of the 
disease. But in milder stages of dementia, co-
gnitive impairment may not be so prominent. 
Previous studies have recommended the use 
of patient self-ratings of subjective QoL in 
mild-moderate dementia [5]. Considering the 
discussion concerning whose preferences to 
use when it comes to the preferences of the 
individual or of the general public, Gold et 
al. (1996, p. 100) [3] write: «To inform pu-
blic policy decisions, one would wish to have 
judgments that are informed, unbiased and 
competent. Problems emerge in meeting the-
se measurement criteria simultaneously both 
for persons who are experiencing the health 
state and for those who are not».
The statement above is true also for the pa-
tient-proxy case. Patients may be regarded 
as not informed or competent at making self-
ratings. Proxies, on the other hand, may not 
be seen as unbiased and consequently may 
not be competent at making ratings of patient 
HRQoL. This poses the problem of choosing 
whose ratings to use.
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patient and proxy ratings should be used in 
CEA’s.
The best way to measure HRQoL in AD for 
CEAs has yet to be established. In order to 
critically appraise health economic asses-
sments in AD and, further, to make informed 
decisions on resource allocation, the issues of 
measuring HRQoL in dementia should be gi-
ven more attention in future research.
ACKNOWLEDGEMENTS
This study was partially funded by the 
County Council of Östergötland, Sweden. 
The authors have had full control over article 
content, interpretation of results, and deci-
sion on publication.
PRIOR/DUPLICATE PUBLICATION
An earlier version of this manuscript has pre-
viously been published in a Ph.D. thesis by 
Jenny Alwin [23]. The manuscript has not 
been previously published in any scientific 
journal.
Health-related quality of life for CEAs ai-
ming to calculate QALYs can be measured 
in different ways, either through so-called 
“direct” (e.g. Time-Trade-Off or Standard 
Gamble) or through “indirect” methods. In 
the present study, HRQoL weights based 
on the EQ-5D instrument (indirect method) 
were used for the model. These methods can 
also be discussed in relation to the theoretical 
framework of welfare economics; this will, 
however, not be explored further in the pre-
sent study.
CONCLUSIONS
In the present study, we have shown that the 
choice of rater – patient self-ratings versus 
proxy ratings – of patients’ HRQoL in AD 
has an important effect on the results of the 
CEA. Following the present value ranges gi-
ven by the NICE for what is considered cost-
effective [1], these differences in results may 
have an important impact on decision making 
and, ultimately, on resource allocation. Based 
on these results we therefore advice that both 
REFERENCES
1. National Institute for Health and Clinical Excellence, Guide to the methods of technology appraisal. London: NICE, 
2008. http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf
2. Hurley J. An overview of the normative economics of the health care sector. In: Culyer AJ, Newhouse J (eds). 
Handbook of health economics. Amsterdam: Elsevier Science, 2000
3. Gold MR, Patrick DL, Torrance GW, et al. Indentifying and valuing outcomes. In: Gold M, Siegel JE, Russell LB, 
et al. (eds). Cost-effectiveness in health and medicine. Oxford University Press, 1996
4. Dolan P. Whose preferences count? Med Decis Making 1999; 19: 482-6
5. Sands LP, Ferreira P, Stewart AL, et al. What explains differences between dementia patients’ and their caregivers’ 
ratings of patients’ quality of life? Am J Geriatr Psychiatry 2004; 12: 272-80
6. Coucill W, Bryan S, Bentham P, et al. EQ-5D in patients with dementia: an investigation of inter-rater agreement. 
Med Care 2001; 39: 760-71
7. Jönsson L, Andreasen N, Kilander L, et al. Patient- and proxy-reported utility in Alzheimer disease using the Eu-
roQoL. Alzheimer Dis Assoc Disord 2006; 20: 49-55
8. Naglie G, Tomlinson G, Tansey C, et al. Utility-based quality of life measures in Alzheimer’s disease. Qual Life 
Res 2006; 15: 631-43
9. Crespo M, Bernaldo de Quiros M, Gomez MM, et al. Quality of Life of Nursing Home Residents With Dementia: 
A Comparison of Perspectives of Residents, Family, and Staff. Gerontologist 2012; 52: 56-65
10. Ready RE, Ott BR, Grace J. Patient versus informant perspectives of quality of life in mild cognitive impairment 
and Alzheimer’s disease. Int J Geriatr Psychiatry 2004; 19: 256-65
11. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of 
patients for the clinician. J Psychiatric Res 1975; 12(3): 189-98
12. Svensk förening för Kognitiva sjukdomar (SKF), Mini Mental Test/MMT, 2000 (test sheet, Swedish version. From: 
Folstein MF, Folstein SE, McHugh PR “Mini-mental state”. A practical method for grading the cognitive state of 
patients for the clinician. J Psychiatr Res 1975; 12: 189-98
13. Mendiondo MS, Ashford JW, Kryscio RJ, et al. Modelling mini mental state examination changes in Alzheimer’s 
disease. Stat Med 2000; 19: 1607-16
31Farmeconomia. Health economics and therapeutic pathways 2012; 13(1) © SEEd All rights reserved
J. Alwin, T. Brodtkorb
14. Statistics Sweden. Life tables for 2006, divided into men and women. Available at: www.ssd.scb.se [latest accessed 
February 2012]
15. Jönsson L, Eriksdotter Jönhagen M, Kilander L, et al. Determinants of costs of care for patients with Alzheimer’s 
disease. Int J Geriatr Psychiatry 2006; 21: 449-59
16. Jönsson L. Economic evaluation of treatments for Alzheimer’s disease.Doctoral Thesis. Division of Geriatric Epi-
demiology, the Neurotec Department. Stockholm, Sweden: Karolinska Institutet, 2003
17. Brooks R. EuroQol: the current state of play. Health Policy 1996; 37: 53-72
18. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095-108
19. Busschbach JJ, Brouwer WB, van der Donk A, et al. An outline for a cost-effectiveness analysis of a drug for pa-
tients with Alzheimer’s disease. Pharmacoeconomics 1998; 13: 21-34
20. Burström K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the 
EQ-5D. Qual Life Res 2001; 10: 621-35
21. Jönsson L, Lindgren P, Wimo A, et al. Costs of mini mental state examination-related cognitive impairment. Phar-
macoeconomics 1999; 16: 409-16
22. Green C. Modelling disease progression in Alzheimer’s disease: a review of modelling methods used for cost-
effectiveness analysis. Pharmacoeconomics 2007; 25: 735-50
23. Alwin J. Assessment of support interventions in dementia. Methodological and empirical studies. Department of 
Medical and Health Sciences. Linköping, Sweden: Linköping University, 2010
